CSTL NASDAQ
Castle Biosciences, Inc.
1W: -0.7%
1M: +6.4%
3M: +46.9%
YTD: -7.7%
1Y: +54.5%
3Y: +117.0%
5Y: -50.9%
$35.56
+0.30 (+0.87%)
Weekly Expected Move ±5.0%
$32
$34
$36
$37
$39
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
-0.90
Bearish
0 bullish
0 neutral
2 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (82)
Castle Biosciences (NASDAQ:CSTL) Insider Tobin Juvenal Sells 1,034 Shares of Stock
Castle Biosciences (NASDAQ:CSTL) Insider Tobin Juvenal Sells 5,543 Shares of Stock
22,186 Shares in Castle Biosciences, Inc. $CSTL Bought by Tidal Investments LLC
Castle Biosciences, Inc. $CSTL Shares Sold by Bank of America Corp DE
Castle Biosciences, Inc. (CSTL) Is Up 15.46% in One Week: What You Should Know
Does Castle Biosciences (CSTL) Have the Potential to Rally 31.46% as Wall Street Analysts Expect?
Castle Biosciences Approved for Dual Listing on Nasdaq Texas
Arrowstreet Capital Limited Partnership Raises Position in Castle Biosciences, Inc. $CSTL
Castle Biosciences (CSTL) Q2 2026 Earnings Call Transcript
Castle Biosciences raises 2026 revenue guidance to $365M-$375M as TissueCypher volume trends toward 50%-52% growth
Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Castle Biosciences targets $345M-$355M 2026 revenue as TissueCypher volumes grow 58% and AdvanceAD-Tx reaches ~650 orders
Castle Biosciences, Inc. Q1 2026 Earnings Call Summary
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Beats Revenue Estimates
Castle (CSTL) Q1 2026 Earnings Transcript
Earnings Scheduled For May 6, 2026
Castle Biosciences Non-GAAP EPS of -$0.49 in-line, revenue of $83.7M beats by $4.47M
Alkermes' Q1 Earnings & Revenues Beat Estimates, Stock Rises
OCGN Falls on Wider Q1 Loss Despite Strong Pipeline Progress Outlook
EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus
Repligen's Q1 Earnings & Revenues Beat Estimates, Stock Rises
JAZZ Stock Jumps as Q1 Earnings & Sales Surpass Expectations
BioMarin Q1 Earnings Miss, Sales Beat, '26 Revenue Guidance Raised
Krystal Biotech Q1 Earnings & Sales Beat Estimates, Pipeline in Focus
AXSM Q1 Loss Widens, Revenues Jump on Higher Auvelity Sales
Wall Street Analysts Predict an 85.15% Upside in Castle Biosciences (CSTL): Here's What You Should Know
CRISPR Therapeutics' Q1 Loss Wider Than Expected, Sales Miss Estimates
SMMT Q1 Loss Narrower Than Expected, Stock Down on Ivonescimab Setback
KYMR Q1 Earnings Top Estimates, Revenues Gain on GILD Collaboration
AGIO Beats on Q1 Earnings & Sales, Stock Up 13% on New Drug Momentum
Amarin's Q1 Loss Narrower Than Expected, Sales Increase Y/Y
VKTX Q1 Earnings Miss on Higher Phase 3 Development Costs
BHC Q1 Earnings Miss Estimates, Sales Grow on Salix & Solta Strength
ABBV Seeks FDA Nod for Rinvoq Label Expansion in Alopecia Areata
Castle Biosciences (NASDAQ:CSTL) Shares Gap Down on Insider Selling
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Consensus Recommendation of “Moderate Buy” by Analysts
Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year
Castle Biosciences, Inc. (NASDAQ:CSTL) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Castle Biosciences (NASDAQ:CSTL) Insider Sells $483,594.50 in Stock
Tobin Juvenal Sells 20,863 Shares of Castle Biosciences (NASDAQ:CSTL) Stock
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data
AstraZeneca's Imfinzi Secures Approval for Gastric Cancer in the EU
FDA Approves NVS' Cosentyx in Hidradenitis Suppurativa for Adolescents
United Therapeutics Stock Surges 32% in 6 Months: Here's Why
Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma's i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB
Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It?
JNJ Seeks Label Expansion of Multiple Myeloma Drug Tecvayli in the EU
DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma's i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB
LLY Wins CHMP Nod for Olumiant's Expanded Use in Alopecia Areata
REGN & SNY's Dupixent Gets CHMP Nod for Pediatric Use in Urticaria
Castle Biosciences (NASDAQ:CSTL) Shares Gap Down – Here’s Why
RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus
PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View
TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line
PRGO Q4 Earnings Miss, Sales Beat, Stock Down on Weak 2026 View
Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline
Pacira BioSciences Q4 Earnings and Revenues Miss Estimates, Stock Down
Castle Biosciences outlines 2026 revenue target of $340M-$350M as AdvanceAD-Tx launch supports growth strategy
Castle Biosciences Non-GAAP EPS of -$0.08 beats by $0.18, revenue of $87M beats by $6.69M
Castle Biosciences, Inc. (CSTL) Q4 2025 Earnings Call Transcript
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Beats Revenue Estimates
Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results
Castle Biosciences (CSTL) Loses 16.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026
Derek Maetzold Sells 4,017 Shares of Castle Biosciences (NASDAQ:CSTL) Stock
Are You Looking for a Top Momentum Pick? Why Castle Biosciences, Inc. (CSTL) is a Great Choice
26,996 Shares in Castle Biosciences, Inc. $CSTL Acquired by Campbell & CO Investment Adviser LLC
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Average Recommendation of “Moderate Buy” by Analysts
What Makes Castle Biosciences (CSTL) a Good Fit for 'Trend Investing'
Castle Biosciences (NASDAQ:CSTL) Hits New 12-Month High After Analyst Upgrade
Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells $20,380.36 in Stock
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma
Castle Biosciences, Inc. (NASDAQ:CSTL) Receives Average Rating of “Moderate Buy” from Analysts
Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer
Expert Melanoma Panel Recommends Castle Biosciences' DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma
Here's Why 'Trend' Investors Would Love Betting on Castle Biosciences (CSTL)
Castle Biosciences (CSTL) is on the Move, Here's Why the Trend Could be Sustainable